More than 4000 journal articles have been published on the clinical relevance of cystatin C since it was discovered as a marker of GFR in 1979 byDr. Anders Grubb. The rising cost pressures faced by health systems has pushed cystatin C into the forefront of biomarkers that could reduce healthcare costs in relation to accurate measurement of for estimating glomerular filtration rate (GFR).
In light of this Gentian will be promoting its cystatin C assay during the 2022 AACC Scientific Meeting & Clinical Lab Expo. 27 years after the first automated assay for cystatin C was developed, Gentian emphasises the unique prognostic and diagnostic value of cystatin C as a marker that:
Is independent of muscle mass2-8
Estimates GFR without race-adjustment9
Correlates well with GFR within the “creatinine blind area”10
Identifies chronic kidney disease (CKD) earlier than creatinine-based eGFR11
Ensures safety and efficacy of medications with a narrow therapeutic index9,12
Recommended for assessment of Glomerular Filtration Rate(GFR) and kidney function9
Analysing cystatin C and creatinine together can give the physician more accurate information on the patient’s eGFR than creatinine alone. The National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) has, in a joint taskforce, recently recommended increasing the use of cystatin C combined with serum (blood) creatinine, as a confirmatory assessment of GFR or kidney function to secure unbiased diagnostics.
Visit us at booth #4421 to discuss implementing cystatin C in your lab